1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends

Generic Drug Opportunity Assessment : Avanafil (Stendra)

  • January 2014
  • Greystone Research Associates
Report ID: 1973866

Summary

Greystone Research has identified a branded drug that represents an attractive opportunity for generic drug companies. Details of our findings are contained in an insightful assessment.

Overview

Stendra is a phosphodiesterase 5 (PDE5) inhibitor indicated for the treatment of erectile dysfunction (ED). Stendra received FDA NDA approval in April 2012. In June 2013, the drug, which will be marketed outside the U.S. under the brand name Spedra, received EC approval to market the drug in the EU.
The drug is formulated as an oral tablet and is supplied in three dosages: 50 mg, 100 mg and 200 mg. Stendra is intended to be taken no more than once per day and based in clinical trial data has an onset of action of as little as 30 minutes. The drug has the same contraindications as those of competing PDE-5 inhibitors approved fro treating ED.
Vivus intends to market Stendra via third parties. An agreement for marketing in the U.S. was recently concluded and the company now anticipates market entry by the end of 2013.

The Market

For the treatment of ED, Stendra will compete with currently approved and marketed PDE5 inhibitors in the form of oral medications including Viagra (sildenafil citrate), marketed by Pfizer, Inc.; Cialis (tadalafil), marketed by Eli Lilly and Company; Levitra (vardenafil), comarketed by GlaxoSmithKline plc and Schering-Plough Corporation in the U.S.; and STAXYN (vardenafil in an oral disintegrating tablet, or ODT), co-marketed by GlaxoSmithKline plc and Merck & Co., Inc.

Report Highlights

Stendra – The Brand
Avanafil – The Product
Avanafil – The Market
Avanafil – The Opportunity
Manufacturing and Sourcing
Stendra Patents and Exclusivity
Therapeutic Class P4 Certifications
Generic First-to-File Revenue Opportunity
Business Risk Assessment
First-to-File – Probabilistic Scenario

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.

Amrita helps you find the right report:

Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

Purchase Reports From Reputable Market Research Publishers

Global Sexual Dysfunction Drugs Market 2017-2021

  • $ 3500
  • Industry report
  • August 2017
  • by Infiniti Research Limited

About Sexual Dysfunction Drugs Sexual dysfunctions include sexual disorders of men and women that can interfere with their sexual performance, leading to unsatisfied sexual intercourse. The major drugs ...

Female Sexual Dysfunction Global Clinical Trials Review, H2, 2017

  • $ 2500
  • Industry report
  • August 2017
  • by GlobalData

Female Sexual Dysfunction Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Female Sexual Dysfunction Global Clinical Trials Review, H2, 2017" provides an overview ...

Erectile Dysfunction - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017

  • $ 2000
  • Industry report
  • July 2017
  • by Delve Insight

DelveInsight’s, Erectile Dysfunction - Global API Manufacturers, Marketed and Phase III Drugs Landscape, 2017” report provides comprehensive insights about marketed and Phase III products for the Erectile ...


Download Unlimited Documents from Trusted Public Sources

Dysfunction Drug Market and Blood Disease Statistics in the UK

  • September 2017
    7 pages
  • Dysfunction Dru...  

    Blood Disease  

  • United Kingdom  

View report >

Dysfunction Drug Market and Blood Disease Statistics in the UK

  • September 2017
    7 pages
  • Dysfunction Dru...  

    Blood Disease  

  • United Kingdom  

View report >

Dysfunction Drug and Opioid Market in the US

  • August 2017
    18 pages
  • Dysfunction Dru...  

    Opioid  

  • United States  

    North America  

View report >

Related Market Segments :

Dysfunction Drug

ref:plp2014

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.